Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN®), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Pharmacokinetics
- Sponsors mAbxience
- 14 Feb 2018 Status changed from active, no longer recruiting to completed.
- 18 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.